Myriad Genetics (NASDAQ:MYGN) announces the launch of a new patient home collection kit for its GeneSight Psychotropic test.
Patient DNA for the assay is collected with a cheek swab. Afterward, the patient puts the swab in a prepaid pre-addressed shipping envelope for transport back to Myriad for testing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.